Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy. - Wikidata - awgldk - TriplyDB

Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.

Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.

http://www.wikidata.org/entity/Q33803217

about

Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?A naturally occurring substitution in human immunodeficiency virus Tat increases expression of the viral genome Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion.A cationic nanoemulsion for the delivery of next-generation RNA vaccines.Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine.Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates.Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression f

P2860

Q34364357-79F4B917-6765-4896-BDAC-B12DF12D102A Q35155254-460FE724-9967-4D27-B34F-77ADE8BA7FCB Q35558828-A0415461-7CE2-44E9-A723-BADF537B2DD2 Q35600305-D0F42C0D-C7D9-4234-84EA-4722E9112015 Q36162593-CF5224DC-738D-45AD-A52F-21A699406AD3 Q36473694-2A123EAC-4E29-49D4-AC67-AC2875403A25 Q37009569-EAAA422E-F6A0-4094-AF16-824A08E68187 Q37297052-305F7F25-581D-4B3B-9919-04D1FB28F608 Q39699309-7F2FD020-2C69-467D-AE62-2203041A92E8 Q42100401-51A529A2-22BD-4603-B40B-F989447CDEE0 Q57075677-AA5AABB1-B689-4E3D-95C1-B83CAFF32478

P2860

Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.

http://www.wikidata.org/entity/Q33803217

description

2000 nî lūn-bûn

@nan

2000 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Evidence for viral virulence a ...... ciency virus vaccine efficacy.

@ast

Evidence for viral virulence a ...... ciency virus vaccine efficacy.

@en

type

label

Evidence for viral virulence a ...... ciency virus vaccine efficacy.

@ast

Evidence for viral virulence a ...... ciency virus vaccine efficacy.

@en

prefLabel

Evidence for viral virulence a ...... ciency virus vaccine efficacy.

@ast

Evidence for viral virulence a ...... ciency virus vaccine efficacy.

@en

P1433

Q33803217-A5F8F50F-B777-4252-B34A-27F678601406

P1476

Q33803217-5B1A7276-A082-47D9-8E3F-1BEAD95A32A1

P2093

Q33803217-06E9CD98-36C2-4799-9C16-A9D6AB06A6CE

Q33803217-21D1356B-9FC8-4D36-8D97-DD2C4A1185D5

Q33803217-258C14B1-C6A0-4084-BDCA-E58853428B06

Q33803217-36791E9D-D91C-40ED-8AA6-16E6809A16A2

Q33803217-AF39DC70-0F97-4375-8CAA-02DF5C41F9D3

Q33803217-D628CF68-395D-4AE8-A7ED-BB7C5C3B1E78

Q33803217-E7E8F5DD-1A01-40DC-B500-64EEA371E4F1

P2860

Q33803217-03F57991-9E2B-4548-BA4B-78E532F05C64

Q33803217-0876A77B-C87A-4C8D-81BB-7FD09142A592

Q33803217-0CE8A3B5-1222-487D-ABAD-FE1A67C5C612

Q33803217-0CF6FD65-EBD6-4522-99E3-3A4FA9A16A36

Q33803217-17ABF6F6-805D-47C5-93CC-AC9A1FB44061

Q33803217-1B2F83FA-757F-486D-B098-96BE71300C13

Q33803217-1B9B9281-5A0F-4EC9-8BD1-36CB2E96DE4C

Q33803217-1BDB1C68-B073-4B2D-9AEE-92D923B639A9

Q33803217-21D2CB81-BDDA-4B13-82DC-44D0D79E5BD2

Q33803217-3504051D-6D28-418D-94E9-F8F320BE884C

P304

Q33803217-51BA42BD-792D-4E6C-82A5-FEA53D80EA21

P31

Q33803217-A67E89B3-B3A3-41ED-9034-18C7351578AE

P356

Q33803217-F04F6655-98A7-49D4-8797-76E78EB4AB8C

P433

Q33803217-CE060017-87AB-4A0D-AF80-3C5B9AFCC618

P478

Q33803217-0AD48647-60C2-4EDD-9FF0-746981563A9D

P50

Q33803217-69BF13A8-475E-48EB-A15C-CFB53E22DB32

P577

Q33803217-1B3246A1-1F97-42D6-88E7-019AE4D59EB0

P5875

Q33803217-B9D79B6C-8E5B-4B1F-BC3E-952EFAA0C5C8

P698

Q33803217-5E3B997D-63E6-45DD-A596-C107DB9745E4

P932

Q33803217-078E2FAE-9B84-41C4-B8F2-4702C53378AE

P356

JVI.74.9.4017-4027.2000

P1433

Journal of Virology

P1476

Evidence for viral virulence a ...... iciency virus vaccine efficacy

@en

P2093

B E Verstrepen

http://www.w3.org/2001/XMLSchema#string

G Van Der Auwera

http://www.w3.org/2001/XMLSchema#string

H Oostermeijer

http://www.w3.org/2001/XMLSchema#string

P J Ten Haaft

http://www.w3.org/2001/XMLSchema#string

P Mooij

http://www.w3.org/2001/XMLSchema#string

W Koornstra

http://www.w3.org/2001/XMLSchema#string

W M Bogers

http://www.w3.org/2001/XMLSchema#string

P2860

Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.

TREECON for Windows: a software package for the construction and drawing of evolutionary trees for the Microsoft Windows environment

HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates.

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV

Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques.

beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.

Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain.

Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV).

P304

4017-4027

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.74.9.4017-4027.2000

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan L. Heeney

P577

2000-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12560426

http://www.w3.org/2001/XMLSchema#string

P698

10756013

http://www.w3.org/2001/XMLSchema#string

P932

111915

http://www.w3.org/2001/XMLSchema#string